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Primary systemic arterial
vasodilation in cirrhotic patients
To the Editor: The increased plasma volume in cirrhotic
patients with ascites made untenable the ‘underﬁll hypothesis’
secondary to ascites-mediated diminished plasma volume.
Thus, the ‘overﬂow hypothesis’ was proposed in which a
hepatic–renal reﬂex caused renal sodium retention with
resultant plasma and extracellular ﬂuid (ECF) expansion.
The ECF expansion then increases cardiac output and causes
secondary systemic arterial vasodilation. In a recent review
in Kidney International,1 a ﬁgure from an experimental
study supports secondary arterial vasodilation in cirrhosis.1
However, another experimental study demonstrated that
prehepatic portal hypertension caused primary systemic vaso-
dilation followed by increased total body sodium.2
Primary systemic arterial vasodilation, as occurs early in
the splanchnic circulation in cirrhosis, must be distinguished
from ECF volume expansion causing increased cardiac output
and secondary systemic arterial vasodilation (overﬂow
hypothesis). With secondary arterial vasodilation due to
ECF volume expansion blood pressure should be increased or
remain normal because of suppression of the neurohumoral
axis including plasma norepinephine (NE), renin-angioten-
sin-aldosterone system (RAAS), and arginine vasopressin
(AVP). However, as cirrhotic patients progress from compen-
sated to decompensated to hepatorenal syndrome (HRS),
there is a progressive decline in systemic vascular resistance
and decreased blood pressure. Moreover, there is a progres-
sive rise in plasma NE, plasma renin activity, and AVP with
resultant hyponatremia during progression of cirrhosis to
HRS, all known risk factors for increased mortality in
cirrhosis.3 Thus, the ‘primary systemic arterial vasodilation
hypothesis’ causing arterial underﬁlling (Figure 1) has been
proposed to explain the pathogenesis of renal sodium and
water retention in cirrhotic patients.4
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on our review in which we proposed2 that the stimulus
initiating and maintaining salt retention in cirrhosis is located
in the liver (that is, in a hepatic ‘volume’ sensor). Dr Schrier
suggests that the syndrome of worsening extracellular ﬂuid
volume (ECFV) expansion plus low blood pressure and
activation of the neuro-humoral axis of ECFV control in
advanced cirrhosis and hepatorenal syndrome is best
attributed to primary systemic vasodilation because secondary
vasodilation due to ECFV expansion would not lower blood
pressure plus would suppress the neuro-humoral axis, and
Albillos et al.3 found systemic vasodilation before sodium
retention in portal hypertension. Although the hemodynamic
and neuro-humoral response to ECFV expansion in normal
conditions would be as he stated, there is no a priori reason
why it should be the same in diseases where homeostatic
responses to abnormal stimuli frequently cause unpredictable
changes. Indeed, patients with congestive heart failure due to
obstructive pulmonary disease4 and patients with edema due
to severe chronic anemia,5 have ECFV expansion, low blood
pressure, systemic vasodilation and activated neuro-humoral
axis of ECFV control. A similar phenotype is also found in
pregnancy wherein the reason for it also remains unex-
plained.6–8 Concerning the study of Albillos et al.,3 leaving
aside the experimental difﬁculties in accurately measuring
systemic hemodynamics in anesthetized rodents, these work-
ers constricted the portal vein and thus created a model quite
different from cirrhosis. In sum, we believe that the available
evidence best supports the presence of a hepatic ‘volume’
sensor that is pathologically activated during cirrhosis and
that systemic vasodilation is a secondary phenomena. None-
theless, we agree with Dr Schrier’s underlying point that the
current understanding of the stimulus that drives salt
retention in cirrhosis is still in the hypothesis stage.1 Clearly,
experimental work to resolve this issue is urgently needed.
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Figure 1 |Primary systemic arterial vasodilation.
*Not suppressed in spite of plasma volume expansion.
(Schrier RW et al.4)
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